Sanofi: positive data for Dupixent in CPD
(CercleFinance.com) - Sanofi has announced that its Dupixent could become the first biologic drug for chronic obstructive pulmonary disease (COPD), after a pivotal Phase III study showed a significant reduction in exacerbations compared to placebo.
In adults on maximum standard inhaled therapy (triple therapy) with uncontrolled COPD with a type 2 inflammatory signature, the product met its primary endpoint and all secondary endpoints.
Dupixent achieved a 30% reduction in acute moderate and severe COPD exacerbations, as well as significant improvements in lung function, quality of life and respiratory symptoms due to this disease.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
In adults on maximum standard inhaled therapy (triple therapy) with uncontrolled COPD with a type 2 inflammatory signature, the product met its primary endpoint and all secondary endpoints.
Dupixent achieved a 30% reduction in acute moderate and severe COPD exacerbations, as well as significant improvements in lung function, quality of life and respiratory symptoms due to this disease.
Copyright (c) 2023 CercleFinance.com. All rights reserved.